Continuous Glucose Monitoring for Post-kidney Transplantation in Pre-existing Type 2 Diabetes

NCT07271433 | Completed

• 1 other identifier: 23-390
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Use of continuous glucose monitor (CGM) in post kidney transplant patients to better assess changes in glucose levels post kidney transplant

Conditions

Kidney Transplant

Keywords

CGM; Kidney Transplant; Continuous Glucose Monitor

Outcome Measures

Primary Outcomes (6)

• Time in Range (TIR)

  Percent of patients who achieved Time in Range (55 mg/dL to 180 mg/dL Glucose) as measured by the Continuous Glucose Monitor

  6 months

• Hospital Readmission

  Percent of patients who experienced a hospital readmission

  6 months

• Time below range (TBR)

  Percent of patients who achieved Time below range (\<54 mg/dL Glucose) as measured by the Continuous Glucose Monitor

  6 months

• Time above range (TAR)

  Percent of patients who achieved Time above range (181-250mg/dL and \>250 mg/dL Glucose) as measured by the Continuous Glucose Monitor

  6 months

• Rejection

  Percent of patients who experienced a rejection of the transplanted kidney

  6 months

• Delayed graft function

  Percent of patients who experienced delayed graft function

  6 months

Study Arms (1)

Post Kidney Transplant, using CGM

A total of 20 patients that are post kidney transplant, will wear a Continuous Glucose Monitor (CGM) until 3 months post-transplant.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a non-randomized prospective single arm study with a planned enrollment of 20 patients.

You may qualify if:

• Sex: men and women
• Ethnicity: all ethnic groups
• Age: ≥ 18
• Known type 2 diabetes before kidney transplant
• Kidney transplant alone
• On multiple daily insulin injection
• Standard prednisone taper
• Smart phone - compatible with the LibreView App

You may not qualify if:

• Simultaneous pancreas-kidney transplant
• Allergy to Freestyle Libre components including adhesive
• Use of vitamin C at doses 500 mg or greater
• Blood dyscrasias that prevent hemoglobin A1c interpretation
• Lack of mobile app accessibility
• Rapid prednisone taper

Sponsors & Collaborators

• The Cleveland Clinic: lead
• Abbott Medical Devices: collaborator

Study Sites (1)

The Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 26, 2025
• First Posted: December 9, 2025
• Study Start: January 29, 2024
• Primary Completion: November 12, 2024
• Study Completion: January 1, 2026
• Last Updated: February 23, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)